Resources Investment Advisors, Llc. Intellia Therapeutics, Inc. Transaction History

Resources Investment Advisors, Llc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$58.27 - $118.99 $113,626 - $232,030	-1,950 Closed	0 $0
Q4 2021 Feb 23, 2022	SELL	$100.76 - $138.36 $99,047 - $136,007	-983 Reduced 33.52%	1,950 $231,000
Q3 2021 Nov 05, 2021	BUY	$132.37 - $176.78 $35,078 - $46,846	265 Added 9.93%	2,933 $393,000
Q2 2021 Aug 09, 2021	SELL	$60.88 - $161.91 $206,383 - $548,874	-3,390 Reduced 55.96%	2,668 $431,000
Q1 2021 May 10, 2021	SELL	$46.59 - $83.68 $2,469 - $4,435	-53 Reduced 0.87%	6,058 $486,000
Q4 2020 Feb 08, 2021	BUY	$18.83 - $63.53 $115,070 - $388,231	6,111 New	6,111 $332,000
Q1 2020 May 14, 2020	SELL	$9.44 - $15.58 $101,008 - $166,706	-10,700 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$10.43 - $17.67 $111,601 - $189,069	10,700 New	10,700 $156,000
Q3 2019 Nov 08, 2019	SELL	$13.07 - $18.51 $113,029 - $160,074	-8,648 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$13.88 - $18.41 $45,110 - $59,832	3,250 Added 60.21%	8,648 $0
Q1 2019 May 10, 2019	BUY	$12.79 - $17.62 $69,040 - $95,112	5,398 New	5,398 $0

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

Stay updated on Resources Investment Advisors, Llc. with notifications on news.